
US life sciences company Illumina’s offer to cut prices and allow rivals continued access to its technologies has “yet to convince” EU antitrust regulators scrutinising its $8 billion cash-and-stock bid for Grail, reported Reuters.
Such doubts could mean that Illumina may have to sweeten its package of proposed remedies if it wants to win EU approval for the acquisition of the cancer detection test maker which it completed last August. Illumina has kept Grail as a separate company prior to regulatory approval.
The European Commission declined to comment, saying its investigation was ongoing, while Illumina said it was working constructively with the EU competition enforcer in order to resolve their doubts or concerns.
Grail is one of the world’s foremost makers of Cancer detection tests, with its ‘Galleri’ test being used to detect up to 50 types of cancer before symptoms appear. The company was originally part of Illumina, until it was spun off in 2016.
“The submitted remedies underscore our commitment to our oncology customers, to whom we have guaranteed continued supply of our products, equal access to technology, and a significant decrease in prices,” the company said in a statement.
“Illumina will accelerate the adoption of GRAIL’s test in Europe years faster than GRAIL could on its own, saving tens of thousands of lives in the EEA (European Economic Area) and billions of euros in healthcare costs.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Senators Urged to Expedite Gail Slater’s Confirmation as DOJ Antitrust Chief
Feb 11, 2025 by
CPI
Former Michigan Asphalt Executive Pleads Guilty in Bid-Rigging Scheme
Feb 11, 2025 by
CPI
Ballard Spahr Expands Litigation Team with Addition of Antitrust Attorney in Seattle
Feb 11, 2025 by
CPI
Portuguese Court Overturns €225 Million Fine for Banking Collusion Due to Statute of Limitations
Feb 11, 2025 by
CPI
Binance and SEC Request Stay in Crypto Lawsuit Amid New Regulatory Task Force
Feb 11, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon